亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Synthesis of Novel Analogues of Matrine and Anti-Tumor Activity Assessment

        2022-04-20 12:11:14QIANMingchengJIANGXinyuQIYingLIUHuiminZHOUKuoZHAOShuaiCHENXin

        QIAN Mingcheng, JIANG Xinyu, QI Ying, LIU Huimin, ZHOU Kuo, ZHAO Shuai, CHEN Xin

        (School of Pharmacy, Changzhou University, Changzhou 213164, China)

        Abstract:In this article, a series of matrine analogues with ring-opening in the lactam portion of the molecule were synthesized and assessed against four cancer cell lines. The in vitro cytotoxicity study exhibited that analogue C4 with a naphthyl ring displayed the best antiproliferative activity compared to its parent compound matrine and other lactam ring-opening analogues. Taken together, the anti-tumor potential lead compound C4 was discovered, which could be used for further study.

        Key words: matrine; structure activity relationship; anti-tumor activity

        Matrine (1), an alkaloid extracted from the roots ofSophoraflavescens, shows wide pharmacological activities, such as anti-cancer, anti-inflammation, anti-viral, anti-nociceptive, and anti-arrhythmic effects[1-6]. Recently, matrine has been extensively studied as a potential anti-tumor agent against various cancer cell lines. Nevertheless, the activity of matrine is restricted owing to its low efficacy and short half-life[7]. To overcome these drawbacks, some studies have focused on modifying the structure of matrine to improve its pharmacodynamics and pharmacokinetics[7].

        Recently, several matrine analogues without a lactam ring (Fig.1) have been synthesized and displayed moderate to higher potency against HCV and tumors[1,6,8-10]. Among them, the carboxylic acid group in the analogues plays a vital role in anti-HCV activity[8]. However, matrinic acid (2) and its corresponding esters lack antiproliferative activity[1]. Interestingly, when the acid was converted into an amide, analogue3regained moderate anti-tumor activity[9]. Moreover, structure-activity relationships (SARs) indicated that the amide bond is essential for the anti-cancer activity of matrine[1].

        We have focused on structure modification of natural products and synthetic methodology for long time[10-12]. Our previous study discovered that some matrine analogues derived from the lactam ring-opening exhibited good anti-tumor activity[10]. Especially, the compoundB3with ameta-bromide on the phenyl ring showed the best antiproliferative activity. Furthermore,B3induced cell cycle arrest in G1 phase and cell apoptosis in a dose-dependent manner on A549 cells. Herein, we report a series of matrine analogues with ring-opening in the lactam portion and with various substituents in the phenyl ring to further study their potential structure-activity relationships.

        Fig.1 Structures of matrine and lactam ring-opening analogues of matrine[7-10]

        1 Experimental Section

        1.1 Chemistry

        C1

        C1is 4-((1R,3aS,3a1S,10aR)-2-benzoyldecahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-N-(m-tolyl)butanamide.

        To a solution of compoundB1(200 mg,0.57 mmol) in 10 mL dichloromethane was added triethylamine (59 μL). Then, benzoyl chloride (78 μL) was added to the reaction solution dropwise and stirred at room temperature for 1 h. After reaction, the solvent was removed under reduced pressure to give the crude product, which was further purified by silica column chromatography (eluting withV(DCM)∶V(MeOH)=50—40) to furnish a white solidC1(225 mg) in 87% yield. M.p.79—85 ℃.1H NMR (400 MHz, CDCl3):δ1.17 (t, 1H,J=1.8 Hz), 1.36 (s, 1H), 1.44—1.53 (m, 4H), 1.58—1.70 (m, 3H), 1.77—1.91 (m, 4H), 2.11 (s, 1H), 2.25 (s, 3H), 2.32 (t, 2H,J=2.5 Hz), 2.46—2.49 (m, 2H), 3.00 (q, 1H,J=1.8 Hz), 3.10 (t, 2H,J=2.5 Hz), 3.43 (dd, 1H,J1=3.5 Hz,J2=1.7 Hz), 3.61—3.67 (m, 1H), 4.18 (s, 1H), 6.85 (d, 1H,J=7.5 Hz), 7.11 (t, 1H,J=2.0 Hz), 7.35—7.50 (m, 7H).13C NMR (100 MHz, CDCl3):δ1.14, 8.67, 19.96, 21.59, 22.31, 26.82, 27.09, 35.58, 36.39, 38.46, 46.66, 56.31, 63.98, 117.04, 120.58, 124.72, 127.23, 128.31, 128.69, 128.81, 129.80, 130.35, 132.07, 136.66, 138.57, 138.69, 172.14, 173.53. HRMS (ESI):m/z[M+H]+calcd for C29H38N3O2: 460.295 9; found: 460.296 0.

        C2is 4-((1R,3aS,3a1S,10aR)-2-benzoyldecahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-N-(3-fluorophenyl)butanamide.

        Following the same procedure asC1,C2was obtained as a white solid in 98% yield. M.p. 165—167 ℃.1H NMR (400 MHz, CD3OD):δ1.29—1.59 (m, 7H), 1.60—1.79 (m, 6H), 1.89 (s, 1H), 1.99 (d, 3H,J=11.64 Hz), 2.42 (s, 2H), 2.83 (q, 2H,J=10.99 Hz), 3.36—3.47 (m, 1H), 3.57—3.73 (m, 1H), 6.80 (t, 1H,J=7.72 Hz), 7.24—7.31 (m, 2H), 7.44 (s, 5H), 7.57 (d, 1H,J=11.40 Hz).13C NMR (100 MHz, CD3OD):δ21.59, 21.95, 23.52, 29.42, 35.75, 37.34, 41.02, 57.37, 57.48, 63.92, 107.79, 108.06, 111.14, 111.35, 116.28, 127.81, 129.54, 130.74, 131.09, 131.18, 141.73, 141.84, 163.04, 165.45, 174.27. HRESIMS:m/z[M+H]+calcd for C28H35FN3O2: 464.270 8; found: 464.270 4.

        C3is 4-((1R,3aS,3a1S,10aR)-2-benzoyldecahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-N-(3-bromophenyl)butanamide.

        Following the same procedure asC1,C3was obtained as a white solid in 98% yield. M.p. 111—113 ℃.1H NMR (300 MHz, CD3OD):δ1.29—1.43 (m, 3H), 1.51—1.85 (m, 9H), 2.44—2.48 (m, 3H), 2.88 (s, 1H), 3.07—3.16 (m, 2H), 3.48—3.62 (m, 2H), 4.12 (s, 1H), 7.20—7.23 (m, 2H), 7.44—7.51 (m, 6H), 7.94—8.02 (m, 1H).13C NMR (75 MHz, CD3OD):δ20.86, 21.03, 23.30, 27.79, 36.03, 37.12, 39.70, 55.46, 57.00, 57.06, 64.59, 119.42, 123.28, 123.71, 127.79, 128.16, 129.34, 129.75, 130.64, 131.29, 131.37, 137.92, 141.51, 174.33, 174.91. HRESIMS:m/z[M+H]+calcd for C28H35BrN3O2: 526.188 7; found: 526.188 9.

        C4

        C4is 4-((1R,3aS,3a1S,10aR)-2-benzoyldecahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-N-(naphthalen-2-yl)butanamide.

        Following the same procedure asC1,C4was obtained as a white solid in 95% yield. M.p. 94—96 ℃.1H NMR (400 MHz, CDCl3):δ1.27—1.52 (m, 7H), 1.62—1.74 (m, 4H), 1.85 (s, 3H), 2.49 (d, 2H,J=6.40 Hz), 2.89 (q, 2H,J=10.84 Hz), 3.35—3.41 (m, 1H), 3.58—3.64 (m, 1H), 4.18—4.21 (m, 1H), 7.37—7.46 (m, 7H), 7.37—7.46 (m, 7H), 7.74—7.80 (m, 3H), 8.25 (s, 1H).13C NMR (75 MHz, CD3OD):δ21.21, 21.49, 23.57, 28.65, 30.07, 30.73, 32.74, 35.85, 37.31, 40.37, 55.07, 57.14, 57.21, 64.08, 117.64, 121.24, 125.93, 127.47, 127.93, 128.52, 128.59, 129.52, 129.59, 130.91, 135.21, 137.49, 138.28, 174.33. HRESIMS:m/z[M+H]+calcd for C32H37N3O2: 496.295 9; found: 496.295 4.

        C5is 4-((1R,3aS,3a1S,10aR)-2-acetyldecahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-N-(naphthalen-2-yl)butanamide.

        C5

        Following the same procedure asC1,C5was obtained as a white solid in 98% yield. M.p. 72—74 ℃.1H NMR (400 MHz, CDCl3):δ1.26—1.52 (m, 7H), 1.62—1.86 (m, 9H), 1.98 (s, 1H), 2.10 (s, 3H), 2.45 (t, 2H,J=6.84 Hz), 2.66 (d, 2H,J=10.20 Hz), 2.84—3.01 (m, 0.5H), 3.40 (s, 1H), 3.62—3.65 (m, 0.5H), 4.19—4.26 (m, 1H), 7.35—7.45 (m, 2H), 7.56(dd, 1H,J1=8.80 Hz,J2=1.92 Hz), 7.77(dd, 3H,J1=15.24 Hz,J2=8.56 Hz), 8.23 (s, 1H).13C NMR (75 MHz, CD3OD):δ21.92, 22.44, 23.59, 29.09, 30.09, 30.31, 34.82, 37.64, 40.91, 45.56, 53.45, 57.35, 63.46, 117.68, 121.23, 125.93, 127.45, 128.52, 128.57, 129.51, 132.01, 135.25, 137.45, 172.81, 174.38. HRESIMS:m/z[M+H]+calcd for C27H36N3O2: 434.280 2; found: 434.280 4.

        1.2 Cell culture and MTT assay

        The cell lines of human non-small celllung cancer (A549), human hepatocellular carcinoma (HepG2), human large cell lung cancer (H460) and human breast cancer (MCF-7) cells were cultured separately in Dulbecco’s Modified Eagle Medium (DMEM) containing 4.5 g/L glucose supplemented with 10% FBS and 1% glutamine. All cell lines were maintained at 37 °C in a humidified atmosphere with 5% CO2.

        3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assaywas carried out in 96-well plates. Cancer cells at the log phase of their growth cycle (1.2×104cells/mL) were added to the 96-well plates (100 μL/well) and incubated for 24 h at 37 ℃ in a humidified atmosphere with 5% CO2. After aspirating medium, 100 μL fresh medium containing the test compound at different concentrations was added to the well. After 72 h incubation, 50 μL of 10% MTT solution per well was added and continually incubated for another 4 h. Then, MTT solution was removed and 100 μL DMSO was added to the well. After 10 min at RT, the OD value of each well was measured on a microplate reader (MULTISKAN GO, Thermo Scientific) at 570 nm. In this assay, the negative reference was 0.1% DMSO and 5-Fu as the positive control.

        2 Results and discussion

        2.1 Synthesis

        The synthesis of matrine amide analogues is described in Fig.2. The key intermediateBiwas obtained in 6 steps according to reported protocols[1,10]. Briefly, the lactam ring in matrine was hydrolyzed to give matrinic acid2, followed by esterization with methanol to afford ester4. Subsequently, protection of the amine with Boc yielded5. Then, hydrolysis of ester5in the presence of NaOH furnished the carboxylic acid6. The intermediate acid6was then coupled with various amines in the presence of HATU as the coupling reagent to give the amidesAi. Subsequently, the deprotection of Boc groups with HCl gas afforded compoundsBi. Finally,Biwas coupled with acyl chloride to give the final compoundsCiin good yields.

        Fig.2 Synthesis of final compounds

        2.2 Anti-proliferative activity evaluation

        All newly prepared matrine analogues (C1—C5) were assessed for cytotoxicity by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay against four cancer cell lines (HepG2, A549, H460, and MCF-7). 5-Fluorouracil (5-Fu) was selected as a positive control. Cytotoxicity for all compounds was assessed at 50 μmol/L each for 72 h against four cancer cells (Table 1). Unpredictably, most final compounds showed low anti-proliferative activities, exceptC4, indicating that the amide bond at the N position of matrine unfavorably affected anti-proliferative activity. Our previous study revealed that analogueB3with a meta-bromide on the phenyl ring showed the best anti-proliferative activity[10]. However, in this study a benzoyl group was introduced to the N position ofB3to give analogueC3, which lost anti-proliferative activity for all tested cancer cells. Remarkably,C4having the same benzoyl group asC3displayed moderate cytotoxicity against cancer cells, suggesting that the naphthyl ring of the molecule contributed significantly to its anti-proliferative activity.

        Table 1 Inhibition rates of matrine analogues at 50 μmol/L %

        3 Conclusions

        In conclusion, we designed and synthesized a series of matrine ring-opening amide analogues (C1—C5). The in vitro cytotoxicity study displayed that analogueC4with a naphthyl ring showed the best anti-proliferative activity compared to its parent compound matrine and other analogues (C1—C3andC5). Together, these data indicate thatC4is a potential anti-cancer candidate, which could be used as a lead compound for further anti-cancer study.

        日韩女优一区二区在线观看| 色爱区综合激情五月综合小说| 极品 在线 视频 大陆 国产| 久久精品网站免费观看| 亚洲精品有码日本久久久| 蜜桃日本免费看mv免费版| 国产欧美一区二区精品性色| 成人综合亚洲欧美一区h| 中文字幕色资源在线视频| 亚洲中文字幕久久精品蜜桃| 97精品人妻一区二区三区香蕉| 91亚洲精品福利在线播放| 天堂麻豆精品在线观看| 18禁止看的免费污网站| 东方aⅴ免费观看久久av| 色yeye在线观看| 国产自拍一区在线视频| 国模精品一区二区三区| 久久久久久久99精品国产片| 91久国产在线观看| 国产一区二区三区视频在线观看| 国产啪亚洲国产精品无码| 中国一级毛片在线观看| 国产一级黄色av影片| 夜夜骚久久激情亚洲精品| 成人午夜福利视频镇东影视| 精品人妻中文av一区二区三区| 一区二区三区黄色一级片| 天天做天天爱夜夜爽毛片毛片| 亚洲男同志网站| 国产精品久久久久免费a∨不卡| 亚洲日本高清一区二区| 久久天天躁狠狠躁夜夜躁2014| 可以免费观看的毛片| 激情视频在线观看免费播放| 国产精品毛片无遮挡高清| 成人精品综合免费视频| 91精品在线免费| 亚洲一区二区国产一区| 无码国产福利av私拍| 亚洲色欲Aⅴ无码一区二区|